Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III trials ... in its flagship GLP-1 agonists -- Ozempic for type 2 diabetes and Wegovy for obesity.

According to the World Health Organization, one in eight people worldwide were living with obesity ... deeming the trial a success. While competitors are developing GLP-1 agonists, the trials ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist ... a long list of candidates in clinical trials trying ...

The two companies describe PF-07081532 as a "next-generation" GLP-1 agonist which can be dosed orally once a day and will be tested in type 2 diabetes and obesity.

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...

The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 receptor agonists ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...